EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An Analysis for IDH ‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice

Xianxin Qiu, Liping Liang, Lingchao Chen, Pengjie Hong, Wanzun Lin, Jiabing Liu, Zhirui Zhou, Wenjia Zhu, Tianqi Wu, Mingyuan Pan, Yihua Zhong, Jing Gao und 2 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Xianxin Qiu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Astrocytoma, Isocitrate Dehydrogenase, Brain Neoplasms, Central Nervous System Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Science And Technology Innovation Medical Development Foundation, The National Natural Science Foundation of China, Science and Technology Development Fund of Shanghai Pudong New Area.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

There is ongoing debate regarding the therapeutic approach and prognosis for IDH‐mutant grade 4 astrocytoma, a newly defined subtype of diffuse glioma in the 2021 WHO classification system for central nervous system tumors (WHO CNS 5). The aim of this study was to explore the clinical outcome and prognosticators for newly diagnosed IDH‐mutant grade 4 astrocytoma based on our single institutional data.

Methods

This retrospective analysis included 53 consecutive patients with newly diagnosed IDH‐mutant grade 4 astrocytoma, who underwent radiotherapy between September 2021 and December 2023. All patients were administered concurrent and adjuvant temozolomide. Eleven patients received adjuvant tumor‐treating fields (TTFields).

Results

The median follow‐up was 15.7 months. Twenty patients had tumor relapse; three patients died, all of whom were without TTFields therapy. The median PFS for the entire cohort was 19.3 months, and the median OS was not reached. Univariate analysis indicated patients younger than 40 years ( p = 0.11) or without homozygous deletion of CDKN2A/B ( p = 0.11) tended to have better PFS. In addition, the TTFields group tended to have longer median PFS than the non‐TTFields group in both analyses before and after propensity score matching (PSM) (24.4 vs. 18.5 months, p = 0.097, before PSM; 24.4 vs. 15.9 months, p = 0.080, after PSM). No significant independent prognostic factor was found in the multivariate analysis.

Conclusions

The study reveals important insights into clinical practice for IDH‐mutant grade 4 astrocytoma. Younger age and tumor without deleted CDKN2A/B might be predictive of better outcomes. The addition of TTFields trended towards improved PFS, necessitating prospective clinical trials for further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaIsocitrate DehydrogenaseBrain NeoplasmsCentral Nervous System NeoplasmsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesAgedMutationYoung AdultPrognosisNeoplasm GradingTemozolomide

Stichwörter der Autor:innen

IDH‐mutant astrocytomaprognosisradiotherapytemozolomidetumor‐treating fields

Substanzen

Isocitrate DehydrogenaseTemozolomide

Autor:innen und Institutionen

  • Department of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, China.

ORCID-Profile: Yang Wang

Förderung

  • Beijing Science And Technology Innovation Medical Development Foundation
  • The National Natural Science Foundation of China
  • Science and Technology Development Fund of Shanghai Pudong New Area
  • National Natural Science Foundation of China

Zitieren

APA

Qiu, X., Liang, L., Chen, L., Hong, P., Lin, W., Liu, J., Zhou, Z., Zhu, W., Wu, T., Pan, M., Zhong, Y., Gao, J., Qin, Z., & Wang, Y. (2025). An Analysis for IDH ‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70081

Vancouver

Qiu X, Liang L, Chen L, Hong P, Lin W, Liu J, et al. An Analysis for IDH ‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70081

BibTeX
@article{Qiu2025,
  author = {Qiu, Xianxin and Liang, Liping and Chen, Lingchao and Hong, Pengjie and Lin, Wanzun and Liu, Jiabing and Zhou, Zhirui and Zhu, Wenjia and Wu, Tianqi and Pan, Mingyuan and Zhong, Yihua and Gao, Jing and Qin, Zhiyong and Wang, Yang},
  title = {An Analysis for IDH ‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70081}
}
Kostenlos starten →